BBCC26 2026

Don S. Dizon MD, FACP, FASCO is Jane F. Desforges Chair in Hematology and Oncology at Tufts University. He is the Director of the Pelvic Malignancies Program at Lifespan Cancer Institute, Head of Community Outreach and Engagement at Legorreta Cancer Center, and Director of Medical Oncology at Rhode Island Hospital. Nationally he is the Vice Chair for Diversity, Equity, Inclusion, and Professional Integrity at SWOG Cancer Research Network. He also is a founding member of the Collaboration for Outcomes using Social Media in Oncology. His research foci include novel treatment of ovarian, uterine, and cervical cancers; communication; survivorship after cancer especially in sexuality; professional social media use; and advocacy on behalf of the sexual and gender minoritized (SGM) communities. He is a fellow of the American College of Physicians (FACP) and the American Society of Clinical Oncology (FASCO).

Dr. Ismail Jatoi is Professor in the Division of Surgical Oncology and Endocrine Surgery and holder of the Dale H. Dorn Endowed Chair in Surgery at the University of Texas Health Sciences Center in San Antonio, Texas. He obtained his undergraduate bachelor’s degree from Washington University in St. Louis and his MD and PhD degrees from St. Louis University. He is a Diplomate of the American Board of Surgery and a Fellow of the American College of Surgeons. He completed fellowship training in surgical oncology at the Royal Marsden Hospital in London, England. In recent years, his primary clinical focus has been on the diagnosis and treatment of breast cancer, and his research focuses on issues pertaining to cancer screening and epidemiology, and the management of breast cancer. Dr. Jatoi has published approximately 170 papers, edited, or authored 8 books, and written 8 book chapters. He has published in numerous high-impact journals, including the New England Journal of Medicine, JAMA, Lancet, British Medical Journal, Journal of Clinical Oncology, Lancet Oncology, JAMA Oncology, and the Journal of the National Cancer Institute. Dr. Jatoi has had longstanding interest in implementation science, the design and analysis of cancer clinical trials, and the development of evidence-based clinical practice guidelines. He has previously served as Co-Director of the San Antonio Breast Cancer Symposium (SABCS), the Breast Cancer Executive Committee of the Southwest Oncology Group (SWOG) and is the co-Principal Investigator of the NRG Oncology effort at the University of Texas Health Science Center in San Antonio and serves on the national NRG Oncology Breast Cancer Committee and Working Group.

Prof. Dr. Rajesh Balakrishnan completed MD Radiation Oncology from Christian Medical College Vellore in 2004 and is working at CMC Vellore since then. He was awarded DNB Radiation oncology in 2005. He also had Image Guided RT training at Clatter Bridge Centre of Oncology, Liverpool, United Kingdom and Breast / Genitourinary Radiotherapy training at Peter MacCallum Centre Australia. His current position is Professor, Department of Radiation Oncology, Christian Medical College, Vellore.
He is specialized in treating malignancies with Radiotherapy including Brachytherapy, Chemotherapy, Targeted Therapies and Immunotherapy. He has been part of more than 30 clinical trials (national and international). His main areas of interest include Breast cancer, Brain tumors, Lymphomas, Pediatric tumors, GI/GU Oncology. His special areas of interest include Reirradiation and Radiosurgery. He is a member of various organizations like AROI, ISNO, ISMPO, ESTRO, ESMO, IBS, SIOP, TISS, IBS, ISCR, AMPI etc.
He has been an invited faculty in conferences both nationally and internationally. He has more than 20 publications in peer reviewed journals and is a reviewer in more than 10 journals. He has been guide for many postgraduate students in his institution.

Dr. Debnarayan Dutta is the Senior Consultant & Head of the Department of Radiation Oncology at Amrita Institute of Medical Sciences, Kochi, India. He is a reputed radiation oncologist, worked in Apollo Cancer Hospital Chennai as a senior consultant before joining Amrita. He did his MBBS from National Medical College, Kolkata in the year 1999 and did MD in radiation oncology from the Nilratan Sirkar Medical College, Kolkata from 2003 to 2006. After completing his MD training, he joined Tata Memorial Hospital, Mumbai as neuro-oncologist & stereotactic radiosurgery fellow in 2006. Then he did fellowship in IMRT in head & neck radiation oncology from Tata Memorial Hospital, Mumbai. He was trained at Tata Memorial Hospital after post-graduation for almost 4 years, from 2006 till 2010. He joined Apollo Cancer Hospital Chennai in 2010 as consultant and was an integral part of CyberKnife treatment team. He was awarded the prestigious ‘MERIT’ award for being a promising cancer researcher by the American Society of Clinical Oncology (ASCO) in 2008, presenter in ‘Hosino’ young investigator award at Yokohama Japan 2009, awarded ‘Neucletron Fellowship’ in 2010. He received aboard training from Antoine Lacassagne Cancer Centre, Nice and Oscar Lambret Cancer Centre, Lille, France for CyberKnife. He had a short stint at Munich CyberKnife Centre, Munich. He is one of the first few Cyberknife users in India and regarded as an expert in radiosurgery & SBRT. He received training from Varian SBRT training center at Lisbon, Portugal in 2013 and was part of IBA proton users meeting at Paris in 2014. He is an eminent speaker in radiosurgery and neuro-oncology, with more than 100 national and international presentations in different academic forums. He has 40 indexed publications, 50 indexed abstracts, chapters in three books and is reviewer of few indexed journals. He is persuading his academic interest as PhD student in Vellore Institute of Technology (VIT). His thesis is on molecular prognostication of head & neck cancer.

Professor Ian Kunkler is Consultant in Clinical Oncology at the Edinburgh Cancer Centre, University of Edinburgh. He qualified in Medicine at Cambridge University and undertook clinical training at St Bartholomew’s Hospital in London. After training in general medicine in Nottingham, he moved to Edinburgh and trained in Clinical Oncology under Professor Bill Duncan. He spent a year as a French Government and EEC research fellow in the Department of Curietherapy with Professor Daniel Chassagne and Dr Alain Gerbaulet. He was appointed Consultant in Clinical Oncology in Sheffield, specialising in the treatment of brain tumours, breast cancer and lymphomas. He returned to Edinburgh in 1992 where he is senior specialist in Clinical Oncology for breast cancer.

His research interests are in adjuvant trials of radiotherapy for breast cancer, the development of biosensors in cancer management and the application of telemedicine in cancer care. He is Chief Investigator of the BIG 2-04 MRC/EORTC SUPREMO trial, the PRIME 2 trial and Principal Investigator at Edinburgh University in the European FP7 large scale integrating project (METOXIA) on translating the hypoxic microenvironment. He has edited two editions of Walter and Miller’s Textbook of Radiotherapy and published over 100 articles. He is a past President of the British Oncological Association

Prof. Dr. Dodul Mondal is a Radiation Oncologist and a director at Max Super Speciality Hospital, Saket, New Delhi, India. He covers cancer treatments, such as Radiation, Chemotherapy, Immunotherapy, and Targeted therapy. He is experienced Radiation and Clinical Oncologist with a demonstrated history of working in the hospital & health care industry. He is skilled in Proton Beam Therapy, SRS, SBRT, IMRT, IGRT and Brachytherapy for various malignancies. He is currently working with Indraprastha Apollo Hospitals, Delhi which is first JCI accredited hospital in India. He provides consultancy in setting up new oncology facility including radiation facility also provides analytical information in oncology related market driven services. He has worked as a faculty in Radiation Oncology Department at AIIMS Delhi, NCI.

Dr. Md. Zaker Ullah is a Consultant Oncoplastic Breast & General Surgeon at The Harley Street Clinic, The Holly Private Hospital and Barts Health NHS Trust.
Dr Ullah has a vast range of experience in breast cancer and general surgery. Dr Ullah has trained in a number of world-renowned hospitals including The Royal Marsden, St Mary’s and Royal Free. Dr Ullah has a keen interest in Oncoplastic Breast Surgery and he has been trained in hospitals such as The Royal Marsden Hospital, St Mary’s Hospital & The Royal Free Hospital.
This training has enabled him to gain extensive experience in both benign and malignant breast conditions, as well as inspiring him to introduce the one-stop breast clinic at Whipps Cross Hospital.

Dr. Jabed Iqbal is a Senior Consultant and Pathologist at SingHealth, Singapore. Dr. Iqbal is a pathologist at Singapore General Hospital in the department of histopathology. He obtained his MBBS degree from Dhaka Medical College in Bangladesh. He completed a four-year anatomical and clinical pathology residency training in USA and was certified by the American Board of Pathology in 2006. He has completed one year fellowship training in oncologic pathology at Roswell Park Cancer institute and another fellowship in hematopathology. He also obtained a PhD in molecular biology from Allegheny University of health Sciences (Philadelphia, PA).
Dr. Iqbal’s clinical and research interests include molecular and pathological aspects of hematological and breast malignancies. He has also authored several scientific articles in different peer-reviewed journals.

Dr. Herdee Gloriane C. Luna** is a distinguished Medical Oncologist, cancer researcher, and advocate based in Metro Manila, Philippines, with expertise in **medical oncology, molecular oncology, and precision cancer care**. She currently serves as **Research Head of the Section of Medical Oncology at the National Kidney and Transplant Institute (NKTI)** and practices at several leading institutions, including St. Luke’s Medical Center and the Lung Center of the Philippines.

Dr. Luna is the **Immediate Past President of the Philippine Society of Oncologists (2024)** and has held several leadership roles in oncology organizations and cancer-care initiatives. She is also the **Lead of Molecular Tumor Boards at the Molecular Oncology Society of the Philippines**, promoting genomics-driven multidisciplinary cancer management.

Her academic and research interests focus on **molecular tumor profiling, circulating tumor cells, biomarker-driven oncology, clinical proteomics, and precision medicine**, with particular expertise in breast cancer and lung cancer. She has contributed to research on EGFR-mutant NSCLC, PD-L1 expression, BRCA-associated cancer biomarkers, NKX2-1 alterations, and molecular profiling of metastatic cancers.

Dr. Luna has received several prestigious international recognitions, including the **ASCO International Development and Education Award (ASCO-IDEA)**, **AVON Global Breast Cancer Clinical Scholar Award**, **ESMO Leaders Generation Program (ESMO-LGP) ASIA**, **UICC Grant**, and the **Takeda Science Foundation Scholarship** at the National Cancer Center Hospital East in Japan.

With **17 peer-reviewed publications** and contributions to national clinical practice guidelines, Dr. Luna is actively involved in advancing cancer research, oncology education, patient navigation, shared decision-making, and equitable access to modern cancer care. Her work reflects a strong commitment to translating molecular science and evidence-based oncology into meaningful improvements in cancer outcomes, particularly in low- and middle-resource settings across the Asia-Pacific region.

Prof. Wadasadawala is a leading figure in radiation oncology and a dedicated clinical researcher specialising in breast cancer management. She serves as a professor of radiation oncology at the Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) and the Tata Memorial Centre in Mumbai. She is also a senior faculty member at the Homi Bhabha National Institute. Her pioneering work focuses on optimising radiation therapy to improve patient outcomes and quality of life. She has been a strong advocate for Ultrahypofractionated Radiation Therapy (uHFRT), successfully implementing accelerated treatment regimens that shorten therapy safely and effectively. Her forward-thinking research bridges technology and care, spanning AI-driven breast cosmesis assessment, geriatric oncology risk profiling, and the study of financial toxicity and healthcare economics in cancer management. Holding an MD, a DNB, and a postgraduate diploma in health economics and policy, she brings a holistic, compassionate, and highly academic approach to modern oncology.

Dr Dileep Ramesh Hoysal is a prominent Indian medical professional and academician specialising in the dual domains of endocrine and breast oncology. He currently serves as an associate professor and consultant in the Department of Surgical Oncology at the Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), which is the specialised research and development wing of the renowned Tata Memorial Centre (TMC) in Mumbai, India.
His clinical training includes a Master of Chirurgiae (MCh) super-speciality degree in endocrine and breast surgery. This advanced training qualifies him to treat highly complex, high-risk conditions involving glandular structures and breast tissues. His surgical practice heavily features modern oncoplastic and endoscopic procedures. These techniques prioritise patient-centric oncological safety while simultaneously minimising visible scarring and maximising functional and aesthetic outcomes. Specifically, his operational expertise covers modern breast-conserving oncology, reconstructive breast procedures, and minimally invasive endoscopic surgeries targeting the thyroid, parathyroid, and adrenal glands.
In addition to his surgical caseload, Dr Hoysal is actively committed to clinical research, medical education, and community advocacy. He routinely contributes peer-reviewed scientific correspondence and research to international oncology publications, such as The Breast. He is also a vocal advocate for advanced specialised training, frequently publishing guidance for aspiring medical students regarding the clinical mastery and multidisciplinary career growth available within the fields of endocrine and breast oncology.
Beyond his responsibilities in the operating theatre and academic research panels, he maintains a well-rounded approach to healthcare. Dr Hoysal describes himself as a philosopher and an avid traveller, pulling inspiration from these interests to provide highly empathetic, balanced, and communicative support to patients navigating stressful cancer treatments.

Professor Anna Kirby specialises in treating breast cancer with radiotherapy. Her research goal is to develop and test new radiotherapy techniques that can treat women with breast cancer patients with greater accuracy while minimising side effects. Her focus is on pragmatic clinical research and the immediate translation of research findings into clinical practice.

Professor Kirby graduated with a first-class honours degree in medical sciences from the University of Cambridge in 1995 and undertook her specialist radiotherapy training at The Royal Marsden and Guy’s and St Thomas’ Hospitals. She undertook her MD(Res) degree with Professor John Yarnold at the Institute of Cancer Research, exploring the role of magnetic resonance imaging in improving the accuracy of breast cancer radiotherapy and evaluating the use of a face-down (or prone) treatment position.

Professor Kirby is now chief investigator of the UK HeartSpare Study, a series of three clinical trials which have led heart-sparing breast radiotherapy to become standard of care in many UK hospitals. She has also led research into the use of fluorescent or ‘invisible’ tattoos, which have recently become standard treatment at The Royal Marsden.

Her current research is aimed at optimising techniques for treating women with lymph-node-positive breast cancer by combining breath-hold techniques with new technologies, including volumetric-modulated arc therapy.

Professor Kirby is Chief Clinical Co-ordinator of the national IMPORT studies, which are evaluating partial breast irradiation and simultaneous integrated boost in women at low and high risk of relapse, respectively. She is also a member of the Trial Management Group for the FAST-Forward study, evaluating shorter courses of radiotherapy, and a co-investigator and breast radiotherapy lead on the CORE trial, evaluating the role of stereotactic radiotherapy in treating oligometastatic disease – in which a patient’s cancer has spread to a few organs but has not fully spread around their body. She chairs the breast tumour site working group for the international MR Linac consortium.

Professor Kirby is a lecturer on the MSc Oncology course at the ICR and an examiner for the Royal College of Radiologists. She is also a keen singer, cook and tennis player.

Dr Marina Parton is a medical oncologist in breast cancer at The Royal Marsden. Appointed to The Royal Marsden Consultant Body in 2009, she received her oncology training at The Royal Marsden and carried out her research in neoadjuvant therapy in breast cancer as part of an MD at The Institute of Cancer Research with Professors Dowsett and Smith.

Dr Parton is the lead cancer clinician in The Royal Marsden’s satellite chemotherapy unit, a joint venture with Kingston Hospital and Macmillan Cancer Support, as well as leading breast clinics at The Royal Marsden in Chelsea. She has published in breast cancer research and is principal investigator in a number of clinical trials at The Royal Marsden. She has previously been chair of the Acute Oncology Group at The Royal Marsden, part of the Breast Pathway Group at London Cancer Alliance (LCA) and co-chair of the LCA Chemotherapy Closer to Home Group. She is involved in a number of national educational groups and meetings on early and secondary breast cancer and co-edited Breast Cancer Survivorship: Consequences of Early Breast Cancer Treatment. Dr Parton was a member of the NICE Early Breast Guidelines update (published 2018).

Miss Laura Johnson is a highly accomplished Consultant Oncoplastic and Reconstructive Breast Surgeon based in London. She currently serves as the Network Director for breast surgery across the Barts Health NHS Trust and the Clinical Lead at St Bartholomew's Hospital. She is widely recognized for her patient-centered approach, leadership in clinical research, and expertise in combining advanced breast cancer treatments with aesthetic reconstruction.
She pursued her medical education at Guy's, King's, and St Thomas' Medical School, graduating with her medical degree and an honors degree in 2004. Following her undergraduate training, she dedicated herself to postgraduate research. In 2012, she was awarded a Doctor of Medicine degree for her pioneering work on a novel magnetic technique used for sentinel lymph node biopsies in breast cancer patients.Her higher surgical training was completed within the highly competitive South East and Central London region. To refine her specialized skills in reconstructive aesthetics, she completed a prestigious Training Interface Group National Oncoplastic Fellowship at the world-renowned Royal Marsden Hospital. She also holds a post-graduate certificate in medical education.
Appointed as a Consultant Oncoplastic Breast Surgeon at St Bartholomew's Hospital in 2016, she has built a distinguished career. Beyond her operating schedule, she sits on her trust’s surgical and cancer boards and has been the driving force behind the development of the state-of-the-art Barts Breast Cancer Centre. Nationally, she is the leading UK specialist managing data and raising medical awareness for Breast Implant Associated Anaplastic Large Cell Lymphoma. Her clinical work and compassionate approach to medicine were also showcased on the Channel 5 documentary series, Alice Roberts: Our Hospital Through Time.Highly regarded by peers and patients alike, she focuses heavily on evidence-based medicine to tailor individual treatment choices. She is a member of the Association of Breast Surgeons and maintains full registration with the General Medical Council.

Dr. Najmun Nahar is an Australian-based Senior Radiation Oncologist with over 20 years of clinical experience specializing in the treatment of breast cancer, brain tumors, and Central Nervous System (CNS) malignancies. She earned her medical degree before completing her advanced specialist training in Australia, achieving the prestigious Fellowship of the Royal Australian and New Zealand College of Radiologists (RANZCR) in 2006. Throughout her distinguished career in Western Sydney, she has dedicated herself to providing comprehensive, empathetic patient care through highly integrated, multidisciplinary tumor boards. Dr. Nahar actively collaborates with surgical and medical oncologists across several prominent healthcare facilities, including the Crown Princess Mary Cancer Centre at Westmead Hospital, Blacktown Hospital, and GenesisCare. In addition to her clinical practice, she is deeply committed to oncology research and the mentorship of upcoming medical professionals. She is also widely recognized for her culturally sensitive approach to care, utilizing her multilingual skills to fluently consult with patients in English, Bengali, Hindi, and Urdu.

Dr. Imogen Locke is a highly distinguished consultant clinical oncologist based in London, specializing in the advanced treatment of breast cancer and lung cancer. She maintains a premier clinical practice at the world-renowned The Royal Marsden NHS Foundation Trust, where she provides cutting-edge oncology care. Beyond her direct clinical work, Dr. Locke serves as the National Specialty Adviser for Radiotherapy for NHS England, a major leadership role where she shapes national healthcare policy, advocates for standardizing advanced treatments, and champions the integration of artificial intelligence to reduce clinical waiting times across the country.
Her clinical expertise heavily focuses on risk-adapted radiotherapy for breast cancer, a highly personalized approach that tailors radiation doses to an individual's specific molecular and genetic risk profile. She is also a recognized expert in delivering precision stereotactic radiotherapy for lung cancer patients. Dr. Locke graduated with her medical degree from St. Bartholomew's Hospital in 1994 and later earned a research doctorate from The Institute of Cancer Research in 2008, where her pioneering academic work focused on molecular risk assessment and genetic tracking of the BRCA1 and BRCA2 genes. Please let me know if you would like to explore her academic research publications, details on how to request a consultation, or information regarding her leadership work with NHS England.

Dr. Anjali Shah is a highly qualified medical oncologist based in Mumbai, India, who currently serves as an Assistant Professor in the Department of Medical Oncology at ACTREC, Tata Memorial Centre. She gained extensive training and clinical experience from the prestigious Tata Memorial Hospital, a premier national cancer center. After completing her medical training (MBBS) at B.J. Medical College, she went on to complete her advanced specialization with a DM in Medical Oncology. Her expertise covers the diagnosis, staging, and comprehensive systemic treatment of various cancers.

Prof. Ramy Refaat Youssef Ghali is a Professor of Clinical Oncology at Ain Shams University, Cairo, Egypt, and a highly experienced clinical oncologist with extensive expertise in medical and radiation oncology. He currently serves as Head of the Clinical Oncology Department at Al Salam International Hospital and is the Founder and CEO of Ghali Oncology Center. He has also held senior clinical and academic positions at leading institutions including Ain Shams University Hospitals, Italian Hospital, Ain Shams Specialized Hospital, Hayat Medical Center, and Coptic Hospital.

Prof. Ghali obtained his MB, BCh from Ain Shams University in 1997, followed by a Master’s degree in Radiation Oncology and Nuclear Medicine in 2001 and a Doctorate in Clinical Oncology and Nuclear Medicine in 2007. His postgraduate training and professional development have included international observerships, perceptorships, masterclasses, and workshops in gastrointestinal, breast, colorectal, renal, hematologic, and supportive oncology at renowned institutions including University of Vienna, Jules Bordet Institute in Brussels, Christie School of Oncology in Manchester, Gustave Roussy in Paris, Memorial Sloan Kettering Cancer Center in New York, and Champalimaud Foundation in Lisbon.

He has been actively involved in professional and academic oncology organizations and currently serves as President of the Arab African International Cancer Congress, an ASCO-endorsed meeting. He is a member of the American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO), European Society for Radiotherapy and Oncology (ESTRO), European Association of Neuro-Oncology (EANO), and the Egyptian Medical Syndicate. He is also a member of the United Procurement Authority committee responsible for evaluating new oncology medicines and their indications within treatment protocols in Egypt, a member of the higher oncology committee of the Egyptian Health Insurance Authority, and has served on academic committees involved in the promotion of university professors and assistant professors.

Prof. Ghali has made significant contributions to oncology research and education, with numerous publications and international conference presentations covering breast cancer, colorectal cancer, lung cancer, head and neck malignancies, prostate cancer, malignant pleural mesothelioma, brain metastases, neuro-oncology, cancer supportive care, and treatment-related toxicities. His research has been published in international and regional peer-reviewed journals, and he has contributed as an author to a chapter in the Springer Medical Radiology series. He has also served as an editorial board member and peer reviewer for several medical and oncology journals.

Alongside his clinical and research activities, Prof. Ghali has played an important role in postgraduate medical education. He has been the course coordinator for the chemotherapy curriculum for postgraduate students in Clinical Oncology at Ain Shams University and has contributed to the organization of international academic oncology conferences. His professional interests encompass multidisciplinary cancer care, systemic therapy, radiation oncology, clinical research, supportive oncology, and the advancement of evidence-based cancer treatment.

With more than two decades of experience in clinical oncology, academic medicine, research, and professional leadership, Prof. Ramy Ghali has established himself as an accomplished oncologist and educator with a strong commitment to advancing cancer care, clinical research, and oncology education across Egypt and the wider region.

Dr. Şahin Laçin is an Associate Professor of Medical Oncology and the Head of the Department of Medical Oncology at Koç University Hospital and Koç University School of Medicine in Istanbul, Turkey. He is an accomplished medical oncologist and academic leader with specialized expertise in gastrointestinal and breast cancers, with particular clinical and research interests in hepatocellular carcinoma, pancreatic adenocarcinoma, colorectal cancer and colorectal liver metastases, gastric and gastroesophageal junction cancers, and breast cancer.

Dr. Laçin completed his MD at Istanbul University, Istanbul Faculty of Medicine, followed by residency training in Internal Medicine at the same institution. He subsequently completed his Medical Oncology Fellowship at Hacettepe University Cancer Institute and undertook a 12-month International Research Fellowship in Gastrointestinal Oncology at MD Anderson Cancer Center in Houston, Texas. His international training has contributed significantly to his expertise in multidisciplinary cancer care and clinical research.

His clinical practice encompasses systemic therapy, immunotherapy, conversion strategies, biomarker-driven treatment, antibody-drug conjugates, precision medicine, targeted therapies, comprehensive genomic profiling, and personalized oncology. He has a particular interest in multidisciplinary hepatobiliary oncology and the management of complex gastrointestinal malignancies, including hepatocellular carcinoma, pancreatic cancer, colorectal cancer and colorectal liver metastases.

In addition to his academic and clinical responsibilities, Dr. Laçin plays an active role in the international oncology community. He serves as the ESMO National Representative for Turkey and is President of the International Relations Committee and an Executive Board member of the Turkish Society of Medical Oncology (TSMO/TTOD). He is also a member of the European Society for Medical Oncology (ESMO) and the American Society of Clinical Oncology (ASCO).

Dr. Laçin has authored or co-authored more than 50 indexed publications and has maintained sustained contributions to international clinical research, medical education, and multidisciplinary cancer care. With his combination of academic leadership, international research experience, and specialized expertise in gastrointestinal and breast oncology, he is an active contributor to the advancement of precision and evidence-based cancer treatment in Turkey and internationally.

Dr. Takahiro Kogawa, MD, PhD, is a prominent Japanese oncologist who serves as the Department Director of Early Clinical Development for Cancer at the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (JFCR) in Tokyo. He earned his medical degree from Sapporo Medical University, where he focused heavily on oncology and cancer biology. To further his expertise, he completed a postdoctoral clinical research fellowship in the Breast Medical Oncology department at the prestigious MD Anderson Cancer Center in the United States. He also gained extensive clinical experience at the National Cancer Center Hospital East in Japan, working closely with the Department of Experimental Therapeutics and Breast Medical Oncology. At the JFCR's Advanced Medical Development Center, Dr. Kogawa focuses on leading early-phase clinical trials and advanced drug development strategies. His primary areas of clinical and translational research include breast cancer management, liquid biopsy and biomarkers like circulating tumor DNA (ctDNA), and the development of novel cancer immunotherapies. In addition to his clinical roles, he serves as an Editor-in-Chief for the Journal of Cancer Medicine & Metastasis and frequently collaborates on international clinical trial initiatives, such as the Asian Clinical Trials Network (ATLAS) project, to advance cancer care globally.

Dr. Randima Nanayakkara is a distinguished Sri Lankan Consultant Surgical Oncologist, widely recognized for his clinical expertise in the surgical management of cancer, with a specialized focus on breast oncological surgery. His academic journey in medicine began with an MBBS degree from India, which laid the foundation for his surgical career. He pursued rigorous post-graduate training in Sri Lanka, earning his Doctor of Medicine (MD) in surgery, and achieved international recognition by becoming a Fellow of the Royal College of Surgeons (FRCS) of England and a Member of the Royal College of Surgeons (MRCS) of England. Additionally, his professional credentials include a Fellowship of the College of Surgeons of Sri Lanka (FCSSL) and a Fellowship in Minimal Access Surgery (FMASI). 

Registered with the Sri Lanka Medical Council (SLMC), Dr. Nanayakkara serves the public sector as a Consultant in Surgical Oncology at the North Colombo Teaching Hospital in Ragama, where he treats complex oncological cases and contributes to training the next generation of surgeons. Alongside his public service, he maintains an extensive private practice, consulting at premier healthcare institutions across Colombo, including Asiri Surgical Hospital, Lanka Hospitals, Nawaloka Hospital, and Hemas Hospital. Known for his meticulous approach to patient care, he strictly advocates for structured follow-ups and dedicated clinical reviews, establishing himself as a highly trusted figure in Sri Lanka's oncology community.

Dr. Hee Kyung Ahn is a prominent South Korean medical oncologist specializing in Hematology-Oncology with a dedicated clinical focus on Breast Cancer. She serves as a vital clinical faculty member and physician within the Breast Cancer Center at Samsung Medical Center (SMC) in Seoul, South Korea. Dr. Ahn earned both her Doctor of Medicine (MD) and Master of Science (MS) degrees in internal medicine from the Sungkyunkwan University School of Medicine. Her formative medical training was deeply rooted at Samsung Medical Center, where she completed her residency and served as a clinical fellow. She then advanced her career at Gachon University Gil Medical Center, where she expanded her expertise as an Associate Professor in the Division of Medical Oncology before transitioning her primary clinical practice back to Samsung Medical Center.
Dr. Ahn's clinical and academic endeavors primarily target sophisticated perioperative and systemic therapies for patients with early-stage and advanced breast cancers. She is a heavily active figure in international clinical trials, focusing on targeted therapeutic agents, toxic chemotherapy management, and emerging combination regimens to advance patient care. Her prominent research projects include the collaborative Young-PEARL study, published in The Lancet Oncology, which demonstrated the long-term survival efficacy and quality-of-life benefits of CDK4/6 inhibitors paired with hormone therapies for premenopausal women with metastatic breast cancer.
Dr. Ahn is also deeply integrated into South Korea's premier medical steering groups, having served as the Chair of the 11th Korean Clinical Practice Guideline for Breast Cancer within the Korean Breast Cancer Society. Additionally, she has driven international collaborative efforts through roles such as Secretary of the International Affairs Committee for the Korean Society of Medical Oncology (KSMO) and Secretary of the Breast Cancer Committee for the Korean Cancer Study Group (KCSG)

Dr. Krithika Rangarajan is a prominent Indian medical researcher, radiologist, and data scientist who serves as an Associate Professor in the Department of Diagnostic and Interventional Oncoradiology at the All India Institute of Medical Sciences (AIIMS), New Delhi. She is also the Principal Investigator for the Centre of Excellence for AI in Health at AIIMS Delhi.She holds an MBBS from Delhi University, an MD in Radiology from AIIMS Delhi, a PhD from IIT Delhi, and an FRCR (UK), alongside a post-doctoral fellowship in deep learning for medical imaging. Her clinical specialization focuses on cancer imaging and interventions, particularly for breast and head/neck cancers. Dr. Rangarajan utilizes AI and data science to improve healthcare accessibility with a patient-centric approach. Her notable work includes developing an AI mammography tool with a 99% negative predictive value, which AIIMS transferred to BPL Technologies for commercialization. She also researches AI simulation training for radiologists and strongly advocates for Indian-centric AI models to address local clinical variations missed by Western datasets. Her contributions have earned her the Young Innovator and Practicing Clinician Award from JIPMER and a French Embassy Fellowship in Medical Applied Research.

Prof. Tomas Kron, OAM, is a highly distinguished German-born Australian medical physicist who serves as the Director of Physical Sciences at the Peter MacCallum Cancer Centre in Melbourne, Australia. Widely recognized for his extensive contributions to radiation oncology, medical physics education, and clinical research, he completed his PhD in Germany before migrating to Australia in 1989. Between 2001 and 2005, he gained international expertise at the London Regional Cancer Centre in Canada, where he contributed to commissioning one of the world's first tomotherapy units, before returning to Australia to lead the physical sciences department at Peter Mac. He also holds academic appointments at several prestigious institutions, including the University of Melbourne, RMIT, and the University of Wollongong. His work focuses primarily on translating advanced technological research into improved real-world patient outcomes, with specializations in clinical radiotherapy, dosimetry, and image-guided treatments. He has a keen research interest in advanced physics applications for breast, lung, and pediatric cancers, as well as the clinical implementation of machine learning for adaptive radiotherapy and the development of 3D-printed patient-matched radiation devices. As a prolific researcher, Prof. Kron has co-authored over 600 academic publications and served as the originator for influential textbook projects like 3D Printing in Radiation Therapy.Beyond his local clinical roles, Prof. Kron has maintained a profound global footprint in radiation safety and education for decades. He has served as a consultant for the International Atomic Energy Agency (IAEA) for nearly 30 years, sits on an International Commission on Radiological Protection (ICRP) task group, and is a past president of Medical Physics for World Benefit (MPWB). He also lends his expertise to prominent scientific journals, acting as an associate editor and board member for publications such as Radiotherapy and Oncology and Radiation Measurements. For his immense impact on healthcare and science, Prof. Kron has received numerous prestigious accolades throughout his career. In 2014, he was awarded the Order of Australia Medal (OAM) for his services to medicine, research, and education. He has also received the Distinguished Services Award from the Australasian College of Physical Scientists and Engineers in Medicine (ACPSEM) and a Lifetime Membership Award from the Trans Tasman Radiation Oncology Group (TROG) for his dedicated trial collaboration. Globally, his contributions were highlighted when he was named one of the top 50 medical physicists in the world by the International Organization for Medical Physics (IOMP).

Dr. Wei Loong Jong is an experienced, IMPCB-certified Medical Physicist specializing in radiation oncology, currently serving as the Regional Medical Physics Manager for Icon ASEAN. In this capacity, he oversees clinical radiotherapy standards, quality assurance framework implementations, and safety programs across multiple Southeast Asian centers. He has driven regional expansions and commissioning programs for newly opened facilities, including Bali International Hospital in Indonesia, Island Hospital in Penang, and Prince Court Medical Centre in Kuala Lumpur. Throughout these projects, he led the clinical integration of complex equipment and methods like Varian TrueBeam systems, CT simulation, and advanced techniques such as Deep Inspiration Breath Hold (DIBH) for breast cancer treatments. He earned his Ph.D. in Medical Physics from the Universiti Malaya in 2017, focusing his doctoral research on developing novel radiation dosimetry materials. An active contributor to the academic community, Dr. Jong has garnered over 380 citations for his research on patient-specific quality assurance in precision clinical workflows. He also regularly shares his clinical breakthroughs as a speaker at major regional oncology seminars and international platforms like the European Society for Radiotherapy and Oncology (ESTRO).

Dr. Nam Sang-Eun is an esteemed South Korean general surgeon, medical researcher, and associate professor at Konkuk University Medical Center in Seoul, South Korea. With over 13 years of specialized clinical experience, she has established herself as a leading figure in the surgical treatment of breast and thyroid diseases, operating primarily within the hospital's dedicated Breast Cancer and Thyroid Cancer Centers. 

Dr. Nam's academic foundation began at the prestigious Korea Advanced Institute of Science and Technology (KAIST), where she graduated in 2004. She went on to pursue her medical training at the Konkuk University School of Medicine, earning her master's degree in 2009 before completing her specialized training in general surgery. 

Throughout her career, Dr. Nam has focused on advancing minimally invasive and oncoplastic surgical techniques to improve patient recovery and quality of life. She is highly regarded for her expertise in performing advanced breast cancer robot surgeries, such as robotic mastectomies. By utilizing hidden, five-centimeter incisions near the axilla (armpit), she successfully achieves tumor clearance while prioritizing cosmetic preservation and minimizing physical scarring for her patients. In addition to her oncology practice, she frequently performs thyroidectomies and manages long-term post-operative endocrine care. 

As an active researcher, Dr. Nam contributes significantly to the understanding of metabolic and physiological changes following cancer treatment. Her published clinical studies frequently investigate post-thyroidectomy body alterations, including obesity trends and metabolic shifts within the Korean patient demographic. She also engages in molecular research to analyze the genomic characteristics of breast carcinoma tissues, aiming to advance targeted therapies. Today, she continues to balance her roles as an academic faculty member, clinical researcher, and operating surgeon at Konkuk University Medical Center, where she holds regular clinical consultations and collaborates with international medical platforms to serve both local and global patients.